Seres Therapeutics (MCRB) Projected to Announce Quarterly Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) is projected to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($2.1850) per share and revenue of $0.1790 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing analysts’ consensus estimates of ($1.88) by ($0.20). The company had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $0.36 million. On average, analysts expect Seres Therapeutics to post $-6 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Seres Therapeutics Trading Down 1.0%

Shares of NASDAQ:MCRB opened at $4.80 on Wednesday. Seres Therapeutics has a twelve month low of $4.59 and a twelve month high of $29.98. The company’s 50 day moving average is $6.63 and its 200 day moving average is $9.01. The company has a market cap of $46.46 million, a PE ratio of -0.93 and a beta of 0.09.

Institutional Trading of Seres Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. increased its holdings in Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 89,995 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Seres Therapeutics by 40.9% in the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 21,679 shares during the period. Marshall Wace LLP purchased a new stake in shares of Seres Therapeutics during the 2nd quarter worth about $1,016,000. Vanguard Group Inc. boosted its stake in shares of Seres Therapeutics by 6.8% during the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock worth $6,001,000 after acquiring an additional 19,793 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Seres Therapeutics during the 3rd quarter valued at about $557,000. 59.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MCRB has been the topic of several recent research reports. HC Wainwright started coverage on shares of Seres Therapeutics in a report on Tuesday, June 23rd. They issued a “buy” rating and a $12.00 price objective on the stock. Zacks Research raised shares of Seres Therapeutics to a “hold” rating in a report on Tuesday, June 23rd. Wall Street Zen raised Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings cut Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $17.00.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.